Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U085 - When to Look Deeper: Common Skin Findings as a Harbinger of Genetic Disease

Monday, February 19; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize skin findings that prompt further examination to determine whether genetic testing would be beneficial
  • Choose among the types of genetic testing available and their advantages and disadvantages
  • Identify the preventative screening necessary and optimized treatment regimens for particular genetic diseases


This session will identify the common skin findings that can be signs for systemic genetic diseases. Additionally, we will summarize the localized skin diseases that appear to be the result of post-zygotic mutations which still have potential to affect the patient's children. We will then assess the clinical situations in which genetic testing is appropriate and how to choose the type of genetic testing that would be optimal. Once a diagnosis is rendered, we will discuss the ways in which we can still help patients with incurable diseases.


  • Craiglow, Brittany Gareth, MD: Aclaris Therapeutics Inc. – A(H), C(Fees); Celgene – A(Fees); Concert Pharmaceuticals – C(Grants/Research Funding); Eli Lilly and Company – C(Fees); Pfizer Inc. – A(H), C(Fees), I(NC), SP(H); Regeneron Pharmaceuticals, Inc. – A(H), SP(H); Roivant Sciences – C(Fees); Summers Laboratories – O(H);
  • Lilly, Evelyn, MD: Eli Lilly and Company – E(S), E(SO);
Monday, February 19
4:30 PM
All faculty / Common Skin Findings as a Harbinger of Genetic Disease
Event Details
  • Date
    Monday, February 19
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 25B
  • CME Credits
  • Type
  • Evelyn Lilly, MD, FAAD
  • Brittany Gareth Craiglow, MD, FAAD